Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ranolazine is associated with cardiovascular and metabolic improvement: a win–win for patients with diabetesThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

Ranolazine is associated with cardiovascular and metabolic improvement: a win–win for patients... European Heart Journal (2006) 27,5–6 Editorial doi:10.1093/eurheartj/ehi624 Ranolazine is associated with cardiovascular and metabolic improvement: a win–win for patients with diabetes Rhonda Cooper-DeHoff and Carl J. Pepine University of Florida, College of Medicine, Division of Cardiovascular Medicine, 1600 SW Archer Road, Gainesville, FL, USA Online publish-ahead-of-print 2 November 2005 This editorial refers to ‘Effects of ranolazine on exercise In the last decade, several large, contemporary hyper- tolerance and HbA1c in patients with chronic angina and tension trials have compared regimens containing either diabetes’ by A. Timmis et al., on page 42 b-blockers and/or diuretics with regimens containing calcium antagonists and/or angiotensin-converting enzyme Ranolazine is a novel therapeutic agent which increases (ACE)-inhibitors. Rates of newly diagnosed diabetes are con- exercise duration and time to angina episodes in patients sistently and significantly higher in patients receiving regi- with persistent chronic angina pectoris. These benefits mens containing primarily b-blockers and/or diuretics. have been observed following monotherapy and in combi- Therefore, identification of drugs without adverse, or pre- nation with b-blockers and calcium antagonists. Although ferably, with beneficial metabolic effects is critical to the the mechanism of action of ranolazine is not completely future care of the growing number of patients with diabetes http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Ranolazine is associated with cardiovascular and metabolic improvement: a win–win for patients with diabetesThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

Loading next page...
 
/lp/oxford-university-press/ranolazine-is-associated-with-cardiovascular-and-metabolic-improvement-KpLTDrTm1w

References (10)

Publisher
Oxford University Press
Copyright
© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
ISSN
0195-668X
eISSN
1522-9645
DOI
10.1093/eurheartj/ehi624
pmid
16267073
Publisher site
See Article on Publisher Site

Abstract

European Heart Journal (2006) 27,5–6 Editorial doi:10.1093/eurheartj/ehi624 Ranolazine is associated with cardiovascular and metabolic improvement: a win–win for patients with diabetes Rhonda Cooper-DeHoff and Carl J. Pepine University of Florida, College of Medicine, Division of Cardiovascular Medicine, 1600 SW Archer Road, Gainesville, FL, USA Online publish-ahead-of-print 2 November 2005 This editorial refers to ‘Effects of ranolazine on exercise In the last decade, several large, contemporary hyper- tolerance and HbA1c in patients with chronic angina and tension trials have compared regimens containing either diabetes’ by A. Timmis et al., on page 42 b-blockers and/or diuretics with regimens containing calcium antagonists and/or angiotensin-converting enzyme Ranolazine is a novel therapeutic agent which increases (ACE)-inhibitors. Rates of newly diagnosed diabetes are con- exercise duration and time to angina episodes in patients sistently and significantly higher in patients receiving regi- with persistent chronic angina pectoris. These benefits mens containing primarily b-blockers and/or diuretics. have been observed following monotherapy and in combi- Therefore, identification of drugs without adverse, or pre- nation with b-blockers and calcium antagonists. Although ferably, with beneficial metabolic effects is critical to the the mechanism of action of ranolazine is not completely future care of the growing number of patients with diabetes

Journal

European Heart JournalOxford University Press

Published: Jan 2, 2006

There are no references for this article.